Erika Rijavec

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini, Massimo Di Maïo, Olga Nigro et al. · Journal for ImmunoTherapy of Cancer · 2021 · 144 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone et al. · European Journal of Cancer · 2020 · 117 citations

Life Sciences, Immunology, Oncology +17

Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer

Selene Ottonello, Carlo Genova, Vincenzo Fontana et al. · Frontiers in Immunology · 2020 · 109 citations · Full text

Life Sciences, Immunology, Oncology +17

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna et al. · Cancer Immunology Immunotherapy · 2020 · 93 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Neal Ready, Clarisse Audigier-Valette, Jonathan W. Goldman et al. · Journal for ImmunoTherapy of Cancer · 2023 · 73 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17